Search Browse Earnings

GERON CORP — SlamSEC

GERON CORP

Nasdaq:GERN

Pharmaceutical Preparations·FOSTER CITY, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Semerjian Harout

Revenue

$1.4M

+450.6% YoY

FY 2023

Adj. EBITDA

-$193.5M

-13891.0% margin

FY 2025

Net Income

-$184.1M

-13218.0% margin

FY 2025

EPS (Diluted)

-$0.32

FY 2025

Stock Price

$1.66

+1.2%

2026-03-11

52W Range

$1.04 – $2.01

P/E Ratio

-5.2x

Market Cap

$1.1B

Cash

$79.0M

FY 2025

Total Debt

$165.4M

FY 2025

Net Debt

$86.4M

FY 2025

Enterprise Value

$1.1B

Debt / EBITDA

-0.4x

FY 2023

EV / EBITDA

-5.9x

Employees

—